Aaron Schindeler

Associate Professor

BSC(Hons)/PhD

Aaron.Schindeler@wimr.org.au

Centre for Diabetes, Obesity and Endocrinology Research

Bioengineering & Molecular Medicine Group

Currently open to PHD and Honours students in the topic areas of:

Gene therapy for Brittle Bone Disease PhD Program: https://www.sydney.edu.au/research/opportunities/3415.html

Aaron Schindeler

Biography

A/Prof Aaron Schindeler is the Head of the Bioengineering & Molecular Medicine laboratory. He holds faculty positions at the Westmead Institute for Medical Research and the Faculty of Engineering at the University of Sydney.He received a BSc(Hons) in biochemistry from UQ (1997) and a PhD in biotechnology and biomolecular sciences from UNSW (2004).

He has worked in the field of Neurofibromatosis (NF) research since 2004 and made fundamental discoveries into the mechanism and treatment of musculoskeletal complications of NF1 that have led to improvements in clinical practice. His gene therapy research program current aims to develop a vaccine to prevent NF1 and NF2-related tumour formation.

Research interests

Musculoskeletal Diseases, Genetic Disorders, CRISPR Gene Editing and Adenoviral Associated Vector Delivery, Neurofibromatosis type 1 and NF2-associated Schwannomatosis, Drug Design (including bone-targeted drugs and senolytics), Orthopaedic Research

Adjunct roles

Head, Bioengineering & Molecular Medicine (0.8 Employee of NSW Health) SCHN
Academic Level D (School of Chemical and Biomolecular Engineering, University of Sydney, 0.2 Employee). USYD

Current grants

NHMRC Ideas Grant 2024 – CIA 2024-2027 Gene Therapy for Neurofibromatosis types 1 and 2
Grants.gov (CTF Clinical trial funding) - CIB 2024-2025 Assessing efficacy of L-carnitine supplementation to treat muscle fatigue and weakness in children with NF1. A placebo controlled, blinded clinical trial.
Philanthropic Funding – Rosenthal Bequest – CIB 2021-2024 Centre for Children’s Bone and Musculoskeletal Health.
NHMRC Ideas Grant 2024 – AI 2024-2026 Getting to the Heart of Osteoarthritis (OA): targeting joint-derived micro-RNAs (miRs) to reduce OA-associated cardiovascular disease (CVD) risk
USyd Equipment Grant - CIB 2024-25 OsInDXA-Sys iNSiGHT Small Animal Dual Energy X-Ray Absorptiometry (DXA)/Digital Radiography (DR) System

Affiliations

University of Sydney, Sydney Children's Hospital Networks (SCHN)